Accuracy of Manufacturer-Reported Average Sales Pricing
Effective January 1, 2005, the Medicare Modernization Act of 2003 revised how Medicare Part B reimburses health care providers for physician-administered infused and injected drugs, moving from the average wholesale price to the average sales price (ASP). Congress has directed OIG to assess and submit to Congress a report—no later than January 1, 2023—on the accuracy of ASP information submitted by manufacturers and to include any recommendations on how to improve the accuracy of that information. This study will compare the ASPs for the top 25 highest-expenditure drugs in Medicare Part B to other benchmark prices and explore possible reasons for any potential pricing anomalies we identify.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|September 2021||Centers for Medicare and Medicaid Services||Accuracy of Manufacturer-Reported Average Sales Pricing||Office of Evaluation and Inspections||OEI-BL-21-00330||2022|